Parkinson disease and COVID-19: two pandemics at once
Vol. 36 No. 2 Supl 1 (2020), Consensus, Guidelines and Recomendations
Vol. 36 No. 2 Supl 1 (2020)

Parkinson disease and COVID-19: two pandemics at once

Consensus, Guidelines and Recomendations
https://doi.org/10.22379/24224022292
Published 2021-05-13
Claudia Lucía Moreno López
Neuróloga, especialista en Trastornos del Movimiento. Unidad de Movimientos Anormales, Fundación Cardioinfantil. Sección de Movimientos Anormales, Hospital San José Centro. Grupo de Cirugía Funcional en Trastornos del Movimiento del Hospital San Ignacio. Docente de Neurología, Universidad del Rosario. Neuróloga Clínica Organización Sanitas Internacional. Bogotá, Colombia.
Óscar Bernal-Pacheco
Neurólogo, especialista en Trastornos del Movimiento. Profesor de Neurología, Movimientos Anormales, Universidad Militar Nueva Granada, Hospital Militar Central. Neurólogo, Movimientos Anormales, Fundación Santa Fe. Bogotá Colombia.
Gustavo Barrios Vincos
Neurólogo, especialista en Trastornos del Movimiento. Unidad de Trastornos del Movimiento, Hospital Occidente de Kennedy, Bogotá, Colombia. Profesor Clínico, Postgrado de Neurología, Universidad de La Sabana.
Sonia Catalina Cerquera Cleves
Neuróloga, especialista en Trastornos del Movimiento. Unidad de Neurología, Sección de Movimientos Anormales y Grupo de Cirugía Funcional en trastornos del Movimiento, Hospital Universitario San Ignacio. Sección de Movimientos Anormales, Clínica Universitaria Colombia. Docente de Neurología - Pontificia Universidad Javeriana. Bogotá, Colombia.
PDF (Español)
XML (Español)

Keywords

COVID-19
Parkinson disease
Telemedicine (MeSH)

Abstract

Current global impact of the COVID-19 pandemic has generated new challenges to continue to provide optimal medical care in patients with chronic diseases in need of regular follow-up. The number of persons suffering from Parkinson disease (PD) has exponentially grown up in the last decade and according to the World Health Organization, this disease is expected to keep growing. For this reason, it is important to review some recommendations for treatment and follow-up of PD patients. Current knowledge does not support an increased risk of infection with COVID-19 in people with PD, but advanced age on average and the usual comorbidities of this population are well-known factors that increase mortality of this infection. Telemedicine and other technologies emerge as a powerful tool to deliver optimal clinical care and improve quality of life in the context of the pandemic. Additionally, this review presents recommendations for management of advanced therapies in PD such as deep brain stimulation and infusion therapies as well as useful strategies for adapt physical activities, rehabilitation, and psychosocial well-being during the mandatory lockdown.

https://doi.org/10.22379/24224022292

PDF (Español)
XML (Español)

References

Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939-53.

Dorsey ER, Bloem BR. The Parkinson Pandemic-A Call to Action. JAMA Neurol. 2018;75(1):9-10.

Ferrarese C, Silani V, Priori A, Galimberti S, Agostoni E, Monaco S, et al. An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID). Neurol Sci. 2020;1-5.

Garg D, Dhamija RK. The Challenge of Managing Parkinson's Disease Patients during the COVID-19 Pandemic. Ann Indian Acad Neurol. 2020;23(Suppl 1): S24-7.

Papa SM, Brundin P, Fung VSC, Kang UJ, Burn DJ, Colosimo C, et al. Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. Mov Disord. 2020;35(5):711-5.

Tulisiak CT, Mercado G, Peelaerts W Brundin L, Brundin P Can infections trigger alpha-synucleinopathies? Prog Mol Biol Transl Sci. 2019;168:299-322.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13.

Bhidayasiri R, Virameteekul S, Kim J, Pal PK, Chung S. COVID-19 : An Early Review of Its Global Impact and Considerations for Parkinson ' s Disease Patient Care. 2020;1-10.

Helmich RC, Bloem BR. The Impact of the COVID-19 Pandemic on Parkinson's Disease: Hidden Sorrows and Emerging Opportunities. J Parkinsons Dis. 2020;10(2):351-4.

Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A. SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration. Mov Disord. 2020;35(5):716-20.

Dourmashkin RR, Dunn G, Castano V, McCall SA. Evidence for an enterovirus as the cause of encephalitis lethargica. BMC Infect Dis. 2012; 12:136.

Adhikari SP, Meng S, Wu Y-J, Mao Y-P, Ye R-X, Wang Q-Z, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29.

Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-6.

Willis AW, Schootman M, Evanoff BA, Perlmutter JS, Racette BA. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology. 2011;77(9):851-7.

Nicoletti A, Sofia V, Bartoloni A, Bartalesi F, Gamboa Barahon H, Giuffrida S, et al. Prevalence of Parkinson's disease: a door-to-door survey in rural Bolivia. Parkinsonism Relat Disord. 2003;10(1):19-21.

Hess DC, Audebert HJ. The history and future of telestroke. Nat Rev Neurol. 2013;9(6):340-50.

Achey M, Aldred JL, Aljehani N, Bloem BR, Biglan KM, Chan P, et al. The past, present, and future of telemedicine for Parkinson's disease. Mov Disord. 2014;29(7):871-83.

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-70.

Goetz CG, Stebbins GT, Luo S. Movement Disorder Society-Unified Parkinson's Disease Rating Scale Use in the Covid-19 Era. Mov Disord. 2020.

Abdolahi A, Scoglio N, Killoran A, Dorsey ER, Biglan KM. Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely. Parkinsonism Relat Disord. 2013;19(2):218-21.

Ben-Pazi H, Browne P, Chan P, Cubo E, Guttman M, Hassan A, et al. The Promise of Telemedicine for Movement Disorders: an Interdisciplinary Approach. Curr Neurol Neurosci Rep. 2018;18(5):26.

Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, et al. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017;89(11):1152-61.

Hassan A, Dorsey ER, Goetz CG, Bloem BR, Guttman M, Tanner CM, et al. Telemedicine Use for Movement Disorders: A Global Survey. Telemed J E Health. 2018;24(12):979-92.

Hainque E, Grabli D. Rapid worsening in Parkinson's disease may hide COVID-19 infection. Parkinsonism Relat Disord. 8 de mayo de 2020;

Torres J, Maheswari U, Parthasarathy K, Ng L, Liu DX, Gong X. Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein. Protein Sci. 2007;16(9):2065-71.

Miocinovic S, Ostrem JL, Okun MS, Bullinger KL, Riva-Posse P, Gross RE, et al. Recommendations for Deep Brain Stimulation Device Management During a Pandemic. J Parkinsons Dis. 2020.

Fasano A, Antonini A, Katzenschlager R, Krack P, Odin P, Evans AH, et al. Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience. Mov Disord Clin Pract. 2020;7(4):361-72.

Robbins TW, Cools R. Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective. Mov Disord. 2014;29(5):597-607.

Salari M, Zali A, Ashrafi F, Etemadifar M, Sharma S, Hajizadeh N, et al. Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID-19) Pandemic. Mov Disord. 2020.

Zach H, Dirkx MF, Pasman JW, Bloem BR, Helmich RC. Cognitive Stress Reduces the Effect of Levodopa on Parkinson's Resting Tremor. CNS Neurosci Ther. marzo de 2017;23(3):209-15.

Helmich RC, Bloem BR. The Impact of the COVID-19 Pandemic on Parkinson's Disease: Hidden Sorrows and Emerging Opportunities. J Parkinsons Dis. 2020;10(2):351-4.

van der Kolk NM, de Vries NM, Kessels RPC, Joosten H, Zwinderman AH, Post B, et al. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial. Lancet Neurol. 2019;18(11):998-1008.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Downloads

Download data is not yet available.